FibroGen, Inc (FGEN): Price and Financial Metrics

FibroGen, Inc (FGEN): $1.30

0.06 (-4.41%)

POWR Rating

Component Grades








Add FGEN to Watchlist
Sign Up

Industry: Biotech




#118 of 360

in industry

FGEN Price/Volume Stats

Current price $1.30 52-week high $20.90
Prev. close $1.36 52-week low $0.33
Day low $1.23 Volume 1,140,300
Day high $1.35 Avg. volume 2,603,172
50-day MA $2.02 Dividend yield N/A
200-day MA $1.33 Market Cap 128.40M

FGEN Stock Price Chart Interactive Chart >

FibroGen, Inc (FGEN) Company Bio

Fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is based in San Francisco, California.

FGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

FGEN Latest Social Stream

Loading social stream, please wait...

View Full FGEN Social Stream

Latest FGEN News From Around the Web

Below are the latest news stories about FIBROGEN INC that investors may wish to consider to help them evaluate FGEN as an investment opportunity.

FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript

FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript November 6, 2023 FibroGen, Inc. beats earnings expectations. Reported EPS is $-0.52, expectations were $-0.68. Operator: Hello and welcome to the FibroGen’s Third Quarter 2023 Earnings Call. At this time, all participants are in listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator […]

Yahoo | November 7, 2023

Q3 2023 FibroGen Inc Earnings Call

Q3 2023 FibroGen Inc Earnings Call

Yahoo | November 7, 2023

FibroGen Inc (FGEN) Reports 155% YoY Increase in Q3 2023 Net Revenue

Strong Roxadustat Volume Growth in China and Successful Cost Reduction Plan Boosts Performance

Yahoo | November 6, 2023

FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Yahoo | November 6, 2023

FibroGen Reports Third Quarter 2023 Financial Results

Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer Third quarter net revenue of $40.1 million, an increase of 155% year over year Roxadustat sNDA accepted in China for chemotherapy-induced anemia Robust roxadustat volume growth of 37% in ChinaStrong execution of cost reduction plan reaffirming cash runway into 2026 SAN FRANCI

Yahoo | November 6, 2023

Read More 'FGEN' Stories Here

FGEN Price Returns

1-mo -37.80%
3-mo N/A
6-mo 99.57%
1-year -93.38%
3-year -93.26%
5-year -97.32%
YTD 46.68%
2023 -94.47%
2022 13.62%
2021 -61.98%
2020 -13.52%
2019 -7.32%

Continue Researching FGEN

Here are a few links from around the web to help you further your research on Fibrogen Inc's stock as an investment opportunity:

Fibrogen Inc (FGEN) Stock Price | Nasdaq
Fibrogen Inc (FGEN) Stock Quote, History and News - Yahoo Finance
Fibrogen Inc (FGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!